Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Institute of Human Genetics Munich, |
RCV000021895 | SCV001150030 | pathogenic | Biotinidase deficiency | 2018-07-16 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV000021895 | SCV001227192 | pathogenic | Biotinidase deficiency | 2024-12-12 | criteria provided, single submitter | clinical testing | This sequence change replaces valine, which is neutral and non-polar, with methionine, which is neutral and non-polar, at codon 62 of the BTD protein (p.Val62Met). This variant is present in population databases (rs397507170, gnomAD 0.006%). This missense change has been observed in individual(s) with biotinidase deficiency (PMID: 11313766, 15060693, 17185019, 22698809). ClinVar contains an entry for this variant (Variation ID: 38487). Invitae Evidence Modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) indicates that this missense variant is expected to disrupt BTD protein function with a positive predictive value of 95%. For these reasons, this variant has been classified as Pathogenic. |
Revvity Omics, |
RCV000021895 | SCV002022099 | likely pathogenic | Biotinidase deficiency | 2020-06-15 | criteria provided, single submitter | clinical testing | |
Baylor Genetics | RCV000021895 | SCV004211397 | pathogenic | Biotinidase deficiency | 2024-02-24 | criteria provided, single submitter | clinical testing | |
Fulgent Genetics, |
RCV000021895 | SCV005664994 | pathogenic | Biotinidase deficiency | 2023-12-23 | criteria provided, single submitter | clinical testing | |
Natera, |
RCV000021895 | SCV001460176 | pathogenic | Biotinidase deficiency | 2020-09-16 | no assertion criteria provided | clinical testing |